Tamiflu Developer Calls Hong Kong Tamiflu Restriction ‘Stupid’
This article was originally published in PharmAsia News
A scientist who helped develop Roche Holding's Tamiflu (oseltamivir phosphate) drug says the effort by Hong Kong authorities to restrict dispensing of the drug during a recent flu outbreak was stupid. Authorities advised physicians to limit the drug to patients suffering complications, fearing overuse could cause resistance. Graeme Laver, a professor who helped develop the drug, said the virus on which Tamiflu is based will not mutate into a resistant variety and urged it be given on a non-prescription basis. (Click here for more
You may also be interested in...
In a 1 June speech before the Alliance For a Stronger FDA, US FDA commissioner Stephen Hahn stressed the agency’s vigilance in guarding against consumer use of flawed COVID-19 products. He also made comments about the need for doctors to communicate more with patients. See what he said about the use of telehealth here.
Request for documents and a briefing is part of efforts to ensure federal programs are ‘protected from price gouging.’
Merck’s Frazier Urges Businesses To Use ‘Every Instrument At Their Disposal’ To Reduce Racial Inequity
‘What we have to guard against is that when the streets quiet down … a lot of people are going to go back to their normal lives,’ Merck CEO Ken Frazier says in an interview with CNBC.